Yolanda N Mageto MD MPH (She/Her)
Critical Care Medicine, Interstitial Lung Diseases, Restrictive Lung Disease
Professor, Pulmonary and Critical Care Medicine Texas A&M Section Leader Director of Interstitial Lung Disease Baylor University Medical Center Dallas Texas
Join to View Full Profile
3410 Worth StSte 250Dallas, TX 75246
Phone+1 802-820-6856
Fax+1 214-820-5094
Dr. Mageto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Yolanda Mageto, MD, is a pulmonologist based in Dallas, TX, specializing in critical care medicine and interstitial and restrictive lung diseases. She completed her medical education at Washington University in St. Louis and advanced training at the University of Texas Southwestern and University of Washington. Currently, she serves as a professor of medicine at Texas A&M and Pulmonologist at Baylor University Medical Center Dallas. Dr. Mageto has expertise in respiratory failure and various lung diseases, specifically Interstitial Lung Disease and Sarcoidosis and has contributed to multiple research publications and clinical trials, including work on idiopathic pulmonary fibrosis. She received a CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR.
Education & Training
- University of WashingtonMPH, Epidemiology, 1997 - 1999
- University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 1995 - 1998
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1991 - 1994
- Washington University in St. Louis School of MedicineClass of 1991
Certifications & Licensure
- TX State Medical License 1992 - 2026
- VT State Medical License 2007 - 2018
- WA State Medical License 1995 - 2000
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Publications & Presentations
PubMed
- 18 citationsMeaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Sympo...Ganesh Raghu, Marya Ghazipura, Thomas R Fleming, Kerri I Aronson, Jürgen Behr
American Journal of Respiratory and Critical Care Medicine. 2024-03-15 - 89 citationsRace and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement.Nirav R Bhakta, Christian Bime, David A Kaminsky, Meredith C McCormack, Neeta Thakur
American Journal of Respiratory and Critical Care Medicine. 2023-04-15 - 1 citationsHealth Care Disparities in Pulmonary Fibrosis-Time to Move the Needle Forward.Yolanda N Mageto
JAMA Network Open. 2023-03-01
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
